Recent research spearheaded by the UK Health Security Agency (UKHSA), alongside Imperial College London and Oxford Population Health, has brought to the forefront a critical issue in modern healthcare: the overprescription of antibiotics and its ensuing contribution to the burgeoning problem of antibiotic resistance. This study, generously funded by the Medical Research Foundation and the National Institute for Health and Care Research, underscores the significant role that vaccinations, particularly against Respiratory Syncytial Virus (RSV), could play in alleviating this predicament.
RSV is a prevalent viral infection that typically manifests as mild respiratory symptoms in the general population. However, it has the potential to cause severe illness among vulnerable groups, such as infants and the elderly, often necessitating hospitalisation. Despite being a viral infection, antibiotics are sometimes inappropriately prescribed for RSV due to the challenges faced by healthcare providers in differentiating between bacterial and viral infections in primary care settings. This misstep significantly fuels the global issue of antibiotic resistance.
The research evaluated data concerning antibiotic prescriptions within general practices and occurrences of laboratory-confirmed respiratory infections between 2015 and 2018. It was discovered that approximately 2.1% of antibiotic prescriptions in English general practices were attributed to RSV infections. The demographic receiving the highest number of prescriptions comprised individuals over the age of 75, while infants recorded the highest rate of prescriptions. In response to these illuminating findings, the UK has initiated an RSV vaccination programme. Commencing in September, the programme offers the vaccine to individuals turning 75 on or after the 1st of September, with a supplementary campaign set for those aged between 75 and 79 years in 2024/25. Additionally, pregnant women are offered the vaccine at 28 weeks, thereby conferring immunity to their newborns. It is anticipated that this initiative will avert 70,000 RSV-related illnesses in infants under 12 months and 60,000 illnesses in eligible older adults.
Dr Lucy Miller, a co-author of the study and a modeller at UKHSA, underscores the crucial necessity of employing antibiotics judiciously to address antibiotic resistance. She highlights that diminishing infections through vaccination can significantly decrease the demand for antibiotics, thereby contributing to a reduction in antibiotic resistance. The UKHSA remains committed to monitoring antibiotic prescribing trends and assessing the impact of such interventions.
Professor Céire Costelloe, Visiting Professor of Health Informatics at Imperial College London and senior author of the study, remarks that this research provides the inaugural estimate of RSV-attributable primary care antibiotic prescriptions by antibiotic class. The study suggests that interventions such as vaccines could effectively complement existing strategies devised to curb antibiotic use on a national scale. Steve Russell, the NHS national director for vaccinations and screening, reiterates the global threat posed by antimicrobial resistance and the imperative to curtail unnecessary antibiotic usage. He advocates for eligible individuals to partake in the RSV vaccination offer, as it holds the potential to prevent serious illness and reduce antibiotic prescriptions.
Antimicrobial resistance represents a formidable global public health threat, exacerbated by the excessive and inappropriate use of antibiotics. The UK’s National Action Plan is committed to reducing total antibiotic use by 5% by 2029, placing a strong emphasis on interventions like vaccination to reach this objective. The study’s revelations were supported by various organisations, including the NIHR Imperial Biomedical Research Centre and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance. Dr Angela Hind, Chief Executive of the Medical Research Foundation, accentuates the significance of studies such as this in illuminating the scale of antibiotic prescribing and its pivotal role in driving antimicrobial resistance.
The introduction of the RSV vaccination programme in the UK marks a substantial advancement in the quest to reduce antibiotic prescriptions and combat antibiotic resistance. By preventing RSV infections, particularly in susceptible populations, this vaccine can help mitigate the reliance on antibiotics, thus contributing to the broader, global effort to tackle antibiotic resistance. As the programme progresses, ongoing evaluation of its impact on antibiotic prescribing trends and resistance patterns will be essential to maximise its public health benefits. This proactive approach not only addresses immediate health challenges but also fortifies the healthcare system against future threats posed by resistant infections.
Be the first to comment